


I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office via EFS-Web on September 25, 2007 by Roxanne Holmes.


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wahl <i>et al.</i>	Confirmation No.:	1873
ApplicationNo.:	10/632,151	Art Unit:	1644
Filed:	July 30, 2003	Examiner:	Ron Schwadron
For:	ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS	Attorney Docket No:	0020-00211US

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES
AND
STATEMENTS UNDER 37 C.F.R. § 1.821(f); § 1.821(g); and § 1.825(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (“Notice”) mailed August 28, 2007 in connection with the above-identified application.

Submitted concurrently herewith is a substitute computer readable form (CRF) copy of the Sequence Listing in the form of a text file (.txt) in compliance with 37 CFR § 1.821(e) and a substitute paper copy of the Sequence Listing in accordance with 37 CFR § 1.821(c).

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.